Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
107.00
+0.38 (0.36%)
Jul 1, 2026, 4:00 PM EDT - Market closed
Insmed Revenue
Insmed had revenue of $305.96M in the quarter ending March 31, 2026, with 229.62% growth. This brings the company's revenue in the last twelve months to $819.56M, up 115.09% year-over-year. In the year 2025, Insmed had annual revenue of $606.42M with 66.73% growth.
Revenue (ttm)
$819.56M
Revenue Growth
+115.09%
P/S Ratio
28.30
Revenue / Employee
$492,526
Employees
1,664
Market Cap
23.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 606.42M | 242.72M | 66.73% |
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | 136.47M | 126.63M | 1,287.56% |
| Dec 31, 2018 | 9.84M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 11.50M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 4.42M | -2.50M | -36.18% |
| Dec 31, 2010 | 6.92M | -3.45M | -33.28% |
| Dec 31, 2009 | 10.37M | -1.33M | -11.33% |
| Dec 31, 2008 | 11.70M | 4.12M | 54.32% |
| Dec 31, 2007 | 7.58M | 6.56M | 639.61% |
| Dec 31, 2006 | 1.03M | 894.00K | 682.44% |
| Dec 31, 2005 | 131.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Exelixis | 2.38B |
| Moderna | 2.23B |
INSM News
- 6 days ago - EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis - GlobeNewsWire
- 8 days ago - Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory - PRNewsWire
- 9 days ago - The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms - ETF Trends
- 16 days ago - Mizuho cuts Insmed target, sees buying opportunity after selloff - TheFly
- 22 days ago - Insmed Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Insmed stock price decline a ‘buying opportunity’, says Roth Capital - TheFly
- 23 days ago - Insmed price target lowered to $179 from $180 at JPMorgan - TheFly
- 26 days ago - Insmed price target lowered to $195 from $205 at RBC Capital - TheFly